Retinotopic cortical mapping in objective functional monitoring of macular therapyMarkus Ritter, Allan Hummer, Maximilian Pawloff, Anna A Ledolter, David Linhardt, Michael Woletz, Gabor Gyoergy Deak, Stefan Sacu, Robin Ristl, Dariga Ramazanova, Graham E Holder, Christian Windischberger, Ursula Margarethe Schmidt-Erfurth
28 May 2024
Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedemaAsad Farooq Durrani, Bita Momenaei, Taku Wakabayashi, Sudheshna Vemula, Saagar A Pandit, Jason Hsu, Allen C Ho, Marc J Spirn, Michael A Klufas, Sunir J Garg, James F Vander, Carl D Regillo, Allen Chiang, Ajay E Kuriyan, Yoshihiro Yonekawa
12 February 2024
Heterogeneity in disease activity, frequency of treatments, and visual outcomes among patients with retinal vein occlusion: relationship between injection need and vision with as-needed ranibizumabRobert B Bhisitkul, Peter A Campochiaro, Steven Blotner, Carlos Quezada-Ruiz, Mimi Liu, Zdenka Haskova
30 January 2024
Intravitreal panitumumab and myopic macular degenerationMukharram M Bikbov, Gyulli M Kazakbaeva, Frank G Holz, Songhomitra Panda-Jonas, Leisan I Gilemzianova, Dinar A Khakimov, Jost B Jonas
10 July 2023
Epimacular brachytherapy for previously treated neovascular age-related macular degeneration: month 36 results of the MERLOT randomised controlled trialTimothy L Jackson, Cristina Soare, Caroline Petrarca, Andrew Simpson, James E Neffendorf, Robert Petrarca, Katherine Alyson Muldrew, Tunde Peto, Usha Chakravarthy, Luke Membrey, Richard Haynes, Mark Costen, David H W Steel, Riti Desai, Fiona BishopSee the full list of authors
25 February 2022
Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! RegistryAdrian Robert Hunt, Vuong Nguyen, Jennifer J Arnold, Ian L McAllister, Hemal Mehta, Alessandro Invernizzi, Theodorus Ponsioen, Pierre-Henry Gabrielle, Louise O'Toole, Pavol Kusenda, Socorro Alforja, Daniel Barthelmes, Mark C Gillies
25 January 2022
Ten-year survival trends of neovascular age-related macular degeneration at first presentationCristina Arpa, Hagar Khalid, Shruti Chandra, Siegfried Wagner, Katrin Fasler, Livia Faes, Pakinee Pooprasert, Reena Chopra, Gabriella Moraes, Konstantinos Balaskas, Pearse A Keane, Sobha Sivaprasad, Dun Jack Fu
25 November 2021
OCT-based biomarkers for predicting treatment response in eyes with centre-involved diabetic macular oedema treated with anti-VEGF injections: a real-life retina clinic-based studySimon KH Szeto, Vivian W. K. Hui, Fang Yao Tang, Dawei Yang, Zi han Sun, Shaheeda Mohamed, Carmen K M Chan, Timothy Y Y Lai, Carol Cheung
8 November 2021
Multicentre study of 4626 patients assesses the effectiveness, safety and burden of two categories of treatments for central retinal vein occlusion: intravitreal anti-vascular endothelial growth factor injections and intravitreal Ozurdex injectionsRichard Gale, Claire Gill, Maria Pikoula, Aaron Y Lee, Rachel L W Hanson, Spiros Denaxas, Catherine Egan, Adnan Tufail, Paul Taylor
21 October 2021
Evolution of treatment paradigms in neovascular age-related macular degeneration: a review of real-world evidenceVincent Daien, Robert P Finger, James S Talks, Paul Mitchell, Tien Y Wong, Taiji Sakamoto, Bora M Eldem, Jean-François Korobelnik
21 October 2021
